Submit your email to push it up the queue
DTx Pharma, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for patients with serious diseases. Founded in [year], DTx Pharma focuses on the discovery and advancement of novel drug candidates that leverage its proprietary platform for targeted delivery of therapeutics. With a strong emphasis on precision medicine, the company is dedicated to addressing unmet medical needs in areas such as oncology and rare diseases. DTx Pharma's unique approach combines cutting-edge technology with a commitment to improving patient outcomes, positioning it as a leader in the biopharmaceutical industry. Notable achievements include [key milestones], which underscore its rapid growth and market presence. As DTx Pharma continues to expand its operational reach, it remains committed to transforming the landscape of drug development.
How does DTx Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
DTx Pharma, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
DTx Pharma, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Novartis AG, which provides a framework for its climate commitments and initiatives. As a current subsidiary of Novartis AG, DTx Pharma inherits various sustainability initiatives and targets from its parent company. Novartis has established science-based targets (SBTi) aimed at reducing greenhouse gas emissions across its operations. These initiatives include commitments to the Carbon Disclosure Project (CDP), the RE100 renewable energy initiative, and the Race to Zero campaign, all of which are cascaded to DTx Pharma. While specific reduction targets for DTx Pharma are not detailed, the overarching goals set by Novartis reflect a commitment to sustainability and climate action. This includes a focus on reducing emissions across all scopes, although specific scope data for DTx Pharma is not available. In summary, while DTx Pharma, Inc. does not currently report its own emissions data, it aligns with the climate commitments and reduction initiatives of Novartis AG, which are designed to drive significant progress in reducing carbon emissions and promoting sustainability within the pharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DTx Pharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.